No change in cortical muscarinic M2, M3 receptors or [35S] GTPγS binding in schizophrenia

Life Sciences

Volumn 78, Issue 11, 2006, Pages 1231-1237

  Scarr, Elizabeth ^a,b   Keriakous, Dahlia ^a   Crossland, Nicola ^a   Dean, Brian ^a,b,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Dorsolateral prefrontal cortex; Human; Muscarinic receptors; Schizophrenia

Indexed keywords

CARBACHOL; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; PIMOZIDE; PROCYCLIDINE; REMOXIPRIDE; RISPERIDONE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN CORTEX; CONTROLLED STUDY; DEMOGRAPHY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; WESTERN BLOTTING;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BINDING SITES; CARBACHOL; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; SCHIZOPHRENIA; SULFUR RADIOISOTOPES;

EID: 31744438772     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.06.038     Document Type: Article

References (30)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fourth edition 1994 American Psychiatric Association Washington, DC
2. D.M. Araujo, P.A. Lapchak, and R. Quirion Heterogeneous binding of [3H]4-DAMP to muscarinic cholinergic sites in the rat brain: evidence from membrane binding and autoradiographic studies Synapse 9 1991 165 176
3. C. Bolden, B. Cusack, and E. Richelson Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells Journal of Pharmacology and Experimental Therapeutics 260 1992 576 580
4. F.P. Bymaster, C. Felder, S. Ahmed, and D. McKinzie Muscarinic receptors as a target for drugs treating schizophrenia Current Drug Targets. CNS & Neurological Disorders 1 2002 147 164
5. M.P. Caulfield, and N.J. Birdsall International Union of Pharmacology: XVII. Classification of muscarinic acetylcholine receptors Pharmacological Reviews 50 1998 279 290
6. J.M. Crook, E. Tomaskovic-Crook, D.L. Copolov, and B. Dean Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation Biological Psychiatry 48 2000 381 388
7. J.M. Crook, E. Tomaskovic-Crook, D.L. Copolov, and B. Dean Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment American Journal of Psychiatry 158 2001 918 925
8. B. Dean, J.M. Crook, K. Opeskin, C. Hill, N. Keks, and D.L. Copolov The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia Molecular Psychiatry 1 1996 54 58
9. B. Dean, M. McLeod, D. Keriakous, J. McKenzie, and E. Scarr Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia Molecular Psychiatry 7 2002 1083 1091
10. B. Dean, F.P. Bymaster, and E. Scarr Muscarinic receptors in schizophrenia Current Molecular Medicine 3 2003 419 426
11. B. Dean, L. Gray, D. Keriakous, and E. Scarr A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia Thalamus and Related Systems 2 2004 287 295
12. C.C. Felder, A.C. Porter, T.L. Skillman, L. Zhang, F.P. Bymaster, N.M. Nathanson, S.E. Hamilton, J. Gomeza, J. Wess, and D.L. McKinzie Elucidating the role of muscarinic receptors in psychosis Life Sciences 68 2001 2605 2613
13. D.D. Flynn, G. Ferrari-DiLeo, D.C. Mash, and A.I. Levey Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease Journal of Neurochemistry 64 1995 1888 1891
14. P. Foster Neuroleptic equivalence Pharmaceutical Journal 243 1998 431 432
15. J.I. Friedman, H. Temporini, and K.L. Davis Pharmacologic strategies for augmenting cognitive performance in schizophrenia Biological Psychiatry 45 1999 1 16
16. J. Gonzalez-Maeso, R. Rodriguez-Puertas, A.M. Gabilondo, and J.J. Meana Characterization of receptor-mediated [35S]GTPgammaS binding to cortical membranes from postmortem human brain European Journal of Pharmacology 390 2000 25 36
17. C. Harrison, and J.R. Traynor The [35S]GTPgammaS binding assay: approaches and applications in pharmacology Life Sciences 74 2003 489 508
18. J. Ichikawa, J. Dai, I.A. O'Laughlin, W.L. Fowler, and H.Y. Meltzer Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum Neuropsychopharmacology 26 2002 325 339
19. J. Ichikawa, Z. Li, J. Dai, and H.Y. Meltzer Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism Brain Research 956 2002 349 357
20. N. Keks, C. Hill, K. Opeskin, D.L. Copolov, and B. Dean Psychiatric diagnosis after death: the problems of accurate diagnosis B. Dean T.M. Hyde J.E. Klienman Using CNS Tissue in Psychiatry Research: a Practical Guide 1999 J. Gordon & Breach Science Publishers Sydney 19 37
21. A.E. Kingsbury, O.J. Foster, A.P. Nisbet, N. Cairns, L. Bray, D.J. Eve, A.J. Lees, and C.D. Marsden Tissue pH as an indicator of mRNA preservation in human post-mortem brain Brain Research. Molecular Brain Research 28 1995 311 318
22. D.C. Mash, and L.T. Potter Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain Neuroscience 19 1986 551 564
23. T.J. Raedler, M.B. Knable, D.W. Jones, R.A. Urbina, J.G. Gorey, K.S. Lee, M.F. Egan, R. Coppola, and D.R. Weinberger In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia American Journal of Psychiatry 160 2003 118 127
24. C.B. Ransom, and H. Sontheimer BK channels in human glioma cells Journal of Neurophysiology 85 2001 790 803
25. R. Rodriguez-Puertas, J. Pascual, T. Vilaro, and A. Pazos Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease Synapse 26 1997 341 350
26. I. Slutsky, J. Wess, J. Gomeza, J. Dudel, I. Parnas, and H. Parnas Use of knockout mice reveals involvement of M2-muscarinic receptors in control of the kinetics of acetylcholine release Journal of Neurophysiology 89 2003 1954 1967
27. E.F. Torrey, M. Webster, M. Knable, N. Johnston, and R.H. Yolken The stanley foundation brain collection and neuropathology consortium Schizophrenia Research 44 2000 151 155
28. P. Vanderheyden, G. Ebinger, R. Dierckx, and G. Vauquelin Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia Journal of the Neurological Sciences 82 1987 257 269
29. D.M. Weiner, H.Y. Meltzer, I. Veinbergs, E.M. Donohue, T.A. Spalding, T.T. Smith, N. Mohell, S.C. Harvey, J. Lameh, N. Nash, K.E. Vanover, R. Olsson, K. Jayathilake, M. Lee, A.I. Levey, U. Hacksell, E.S. Burstein, R.E. Davis, and M.R. Brann The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine Psychopharmacology (Berlin) 177 2004 207 216
30. K. Zavitsanou, A. Katsifis, M. Filomena, and H. Xu-Feng Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder Neuropsychopharmacology 29 2004 619 625